Clinical Trials Browser

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Pancreatic Neoplasms

NCT06495125 2026-04-06

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Phase 2 Recruiting

50 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT07481786 2026-04-06

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Phase 3 Recruiting

220 enrolled

CNSThoracic

Adenocarcinoma of Lung, Brain Neoplasms

NCT05665504 2026-04-01

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

Recruiting

250 enrolled

Thoracic

Adenocarcinoma of Lung

NCT07479095 2026-03-20

KETO-FDG Lung

Phase NA Recruiting

30 enrolled

Thoracic

Adenocarcinoma of Lung

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

18 enrolled

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT07012759 2026-03-05

Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients

Recruiting

100 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms, Pleural Effusion

NCT07219251 2026-03-03

EVLC

Phase NA Recruiting

194 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Small Cell Lung Carcinoma

NCT05797168 2026-03-02

FONTANA

Phase 1/2 Recruiting

506 enrolled

GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT07423169 2026-02-20

Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer

Phase NA Recruiting

10 enrolled

Thoracic

Adenocarcinoma of Lung

NCT03199651 2026-02-19

BLCIO

Phase NA Recruiting

3,584 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT07235280 2026-02-19

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

Phase EARLY_PHASE1 Recruiting

48 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Phase 1 Recruiting

240 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04339218 2026-01-30

CRYOMUNE

Phase 3 Recruiting

214 enrolled

Thoracic

Adenocarcinoma of Lung

Clinical Trials

Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Pathogenic Variants in Genes Associated With Lung Adenocarcinoma

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

KETO-FDG Lung

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients

EVLC

FONTANA

Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer

BLCIO

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

CRYOMUNE